Background Image
Menu

Latest News

Catapult Ventures appoints Vijay Curthan as Investment Director; promotes Emma Johnson to Associate

9 April 2020

Catapult Ventures appoints Vijay Curthan as Investment Director; promotes Emma Johnson to Associate

6th April 2020, Alderley Park: Catapult Ventures has announced the appointment of Vijay Curthan as Investment Director in its GM & Cheshire Life Sciences Fund. Vijay joins Catapult with a background in healthcare private equity, investment banking and pharma industry...

Intellin diabetes app enhanced to capture COVID-19 data

8 April 2020

Intellin diabetes app enhanced to capture COVID-19 data

UK company Gendius has enhanced its app for diabetes patient Intellin to capture COVID-19 data after a surge in downloads following the outbreak. Diabetes patients are classified as high-risk by the World Health Organisation (WHO) for developing severe symptoms from the COVID-19...

Clin-e-Cal Rafi-Tone App listed in the COVID19 Health App Formulary

7 April 2020

Clin-e-Cal Rafi-Tone App listed in the COVID19 Health App Formulary

GM&C Life Sciences Fund porfolio company Clin-e-Cal has been listed in the COVID19 Health App Formulary as a trusted digital solution for health management by ORCHA (The Organisation for the Review of Care and Health Apps). As an asthma management and medication adherence...

OBT achieves further milestone in Boehringer Ingelheim collaboration

1 April 2020

OBT achieves further milestone in Boehringer Ingelheim collaboration

The Boehringer Ingelheim drug candidates are two of several assets approaching or in clinical development whose discovery has been enabled by OBT’s proprietary OGAP® target discovery platform … OBT receives milestone payment associated with advance of drug candidate …...

MicroBioSensor - New device for treatment of peritonitis undergoes clinical trials

31 March 2020

MicroBioSensor - New device for treatment of peritonitis undergoes clinical trials

A trial of a medical device which could improve the diagnosis and treatment of peritonitis for patients undergoing peritoneal dialysis, has started in ten major hospitals across the UK. The QuickCheck device has been developed by MicroBioSensor over the past five years in...

The AMR Centre signs agreement with Microbiotix to co-develop treatment for gonorrhoea

18 March 2020

The AMR Centre signs agreement with Microbiotix to co-develop treatment for gonorrhoea

The AMR Centre (AMRC) has today announced a multi-year co-development agreement with Massachusetts-based clinical stage biopharmaceutical company Microbiotix, Inc. to progress a novel treatment to tackle the bacterium that is responsible for gonorrhoea. This innovative project...

Blueberry Therapeutics announces new Clinical Science Lead

12 March 2020

Blueberry Therapeutics announces new Clinical Science Lead

Blueberry Therapeutics are delighted to welcome Kerry Nield as Clinical Science Lead, with responsibility for clinical trial design and pipeline implementation including clinical scientific expertise, clinical strategy and product development planning. Kerry has over 17...

Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease

25 February 2020

Cytox MedNous coverage: Genetic risk assessment in Alzheimer's disease

Dr Alex Gibson, Business Development Officer at Cytox discusses in MedNous how to predict a person’s genetic risk of developing Alzheimer's using Polygenic Risk Scores. First application is identifying patients most suitable to enter clinical trials, based on risk of...

Rinicare receives funding support from Innovate UK

19 February 2020

Rinicare receives funding support from Innovate UK

Rinicare and The University Hospitals of Morecambe Bay NHS Trust are delighted to announce that they have received funding support from Innovate UK to proceed with a joint research project that will collect real-life evidence of the benefits of Rinicare’s SAFE (System to...

Catapult invests in Biohabit through the GM&C Life Sciences Fund

13 February 2020

Catapult invests in Biohabit through the GM&C Life Sciences Fund

Catapult has completed a seed investment into Alderley Park based Biohabit through the Greater Manchester and Cheshire Life Sciences Fund. Biohabit are developing a salivary test for the diagnosis of heart failure, which hopes to replace the need for existing blood tests. By...